Clinical Trials Logo

Filter by:
NCT ID: NCT00263588 Completed - Neoplasms, Breast Clinical Trials

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Start date: December 2, 2005
Phase: Phase 2
Study type: Interventional

Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.

NCT ID: NCT00263042 Terminated - Clinical trials for Cardiovascular Disease

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

CRESCENDO
Start date: December 2005
Phase: Phase 3
Study type: Interventional

The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.

NCT ID: NCT00262600 Completed - Stroke Clinical Trials

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

NCT ID: NCT00262522 Completed - Clinical trials for Human Immunodeficiency Virus Infections

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the safety and tolerability of the to-be-marketed lopinavir/ritonavir (LPV/r) tablet formulation with the marketed soft gel capsule (SGC) formulation and to compare the safety, tolerability, and antiviral activity of once daily (QD) and twice daily (BID) dosing of the LPV/r tablet formulation in combination with select nucleoside reverse transcriptase inhibitors (NRTIs) in patients who have not previously received antiretroviral treatment.

NCT ID: NCT00262236 Completed - Hypertension Clinical Trials

Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.

NCT ID: NCT00261976 Completed - Psoriasis Clinical Trials

A Long-term Safety Study of Infliximab (Remicade)

Start date: February 2002
Phase: Phase 4
Study type: Observational

This is a study evaluating the long-term safety of infliximab (Remicade)

NCT ID: NCT00261950 Completed - Clinical trials for Secondary Hyperparathyroidism

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

BONAFIDE
Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.

NCT ID: NCT00261742 Terminated - Clinical trials for Streptococcal Infections

Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis

Start date: October 2005
Phase: Phase 4
Study type: Interventional

The goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group A beta-hemolytic streptococci.

NCT ID: NCT00261495 Completed - Pain Clinical Trials

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients with chronic non-cancer pain. The study will also determine the dose of sustained-release hydromorphone that provides a level of pain control that is equal to the pain control provided by control-released oxycodone (equi-analgesic dosage).

NCT ID: NCT00261378 Completed - Clinical trials for Primary Liver Cancer

Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation

PRECISIONV
Start date: November 2005
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety and efficacy of DC Beadâ„¢ delivered by intra-arterial embolisation for the treatment of Hepatocellular Carcinoma